Zika vial heading to Hawaii for vaccine work

Mosquito

As the Zika virus continues is worldwide tear, a vial is heading to Hawaii for animal trials on a potential vaccine.

On Tuesday, a state board approved a 2009 application from the university’s Dr. Vivek R. Nerurkar to bring a vial to the school from the CDC in Atlanta, according to KHON. The virus will be used to develop a potential vaccine.

Nerurkar first applied to receive a Zika vial after an outbreak in 2009 in Yap and French Polynesia.

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

The university will now run animal tests, joining other organizations and biopharma companies large and small in trying to combat the virus that has been linked to thousands of microcephaly cases and to cases of Guillain-Barre syndrome.

Separately, this week the WHO updated on a multimillion dollar funding gap in its Zika control efforts that involve 23 health partners. The WHO’s gap is more than $15 million while total shortfalls are more than $47 million, according to an interim report.

However, the WHO rejected a call from scientists and others who asked the agency to support moving the upcoming Olympics from Brazil; the agency said such a change would “not significantly alter the international spread of Zika virus.”

Dozens of organizations and private companies are involved in the Zika vaccine race, with reports surfacing last week that some are being cautious with their development to seek assurance that a potential vaccine would have a market. Some experts are worried that by the time a vaccine could be made, people will start to begin developing natural immunity.

- here’s KHON’s story
more from the Honolulu Star Advertiser
- and more on the WHO updates

Related Article:
Big Pharmas cautious on Zika vaccine development
Inovio moves 'aggressively' toward Zika vax PhI after monkey trial
Baltimore-based Pharos secures Zika vaccine tech
Health agencies inform on Zika vaccine timeline

Read more on

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.